John Sellick1, Kari Mergenhagen2, Lindsay Morris3, Lindsey Feuz4, Amy Horey5, Vineeta Risbood5, Amy Wojciechowski6, Christine Ruh7, Edward Bednarczyk8, Erin Conway5, Michael Ott9. 1. Department of Medicine, Jacobs School of Medicine & Biomedical Sciences, University at Buffalo School of Medicine and Biomedical Sciences, Infectious Diseases, Buffalo, NY; Department of Infectious Diseases, VA Western New York Healthcare System, Buffalo VA Medical Center, Buffalo, NY. 2. Department of pharmacy, VA Western New York Healthcare System, Buffalo VA Medical Center, Pharmacy, Buffalo, NY. Electronic address: kari.mergenhagen@va.gov. 3. Department of pharmacy, VA Western New York Healthcare System, Buffalo VA Medical Center, Pharmacy, Buffalo, NY; Department of Defense, Landstuhl Regional Medical Center, Pharmacy, Landstuhl, Germany. 4. Department of pharmacy, VA Western New York Healthcare System, Buffalo VA Medical Center, Pharmacy, Buffalo, NY; Department of Pharmacy, Buffalo General Medical Center, Pharmacy, Buffalo, NY. 5. Department of pharmacy, VA Western New York Healthcare System, Buffalo VA Medical Center, Pharmacy, Buffalo, NY. 6. Department of Pharmacy, D'Youville College, School of Pharmacy, Buffalo, NY. 7. Department of pharmacy, VA Western New York Healthcare System, Buffalo VA Medical Center, Pharmacy, Buffalo, NY; Department of Pharmacy, Erie County Medical Center, Pharmacy, Buffalo, NY. 8. Department of pharmacy, VA Western New York Healthcare System, Buffalo VA Medical Center, Pharmacy, Buffalo, NY; Department of pharmacy practice, University at Buffalo-The State University of New York, School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY. 9. Department of Pharmacy, Erie County Medical Center, Pharmacy, Buffalo, NY.
Abstract
OBJECTIVE: To measure the incidence and risk factors for fluoroquinolone (ciprofloxacin, moxifloxacin, and levofloxacin)-associated psychosis or delirium in a veteran population. METHODS: A retrospective study was conducted in the Western New York Veterans Affairs Health System (2005-2013). Participants were hospitalized veterans receiving a fluoroquinolone for at least 48 hours (n = 631). Cases of delirium or psychosis were defined by the Diagnostic and Statistical Manual of Mental Disorders-IV criteria, and the Naranjo scale (score ≥ 1) was used to determine the probability of the adverse drug reaction being related to fluoroquinolones. A bivariate analysis of covariates followed by a multivariate logistic regression was used to determine predisposing factors to the development of delirium/psychosis. RESULTS: The mean age of the population was 71.5 years (range: 22-95). Fluoroquinolone-associated delirium/psychosis occurred in 3.7% of the inpatients studied (n = 23). The median Naranjo score was 3 indicating a possible association. Psychosis/delirium occurred in 3.6% of ciprofloxacin-treated patients (n = 14/391), 4.5% of patients-treated with moxifloxacin (n = 9/200), and 0% of those receiving levofloxacin (n = 0/40); p = 0.4. Significant risk factors for development of delirium/psychosis in patients receiving a fluoroquinolone in the multivariate logistical regression included typical antipsychotic use (OR, 5.4; 95% CI: 1.4-16.7) and age. A 10-year increase in age was associated with a 1.8-fold greater odds of a neuropsychiatric event. CONCLUSIONS: Fluoroquinolones may be more commonly associated with delirium/psychosis than originally reported in this veteran population. Caution should be used when prescribing a fluoroquinolone for patients on typical antipsychotics and those of advanced age. Published by Elsevier Inc.
OBJECTIVE: To measure the incidence and risk factors for fluoroquinolone (ciprofloxacin, moxifloxacin, and levofloxacin)-associated psychosis or delirium in a veteran population. METHODS: A retrospective study was conducted in the Western New York Veterans Affairs Health System (2005-2013). Participants were hospitalized veterans receiving a fluoroquinolone for at least 48 hours (n = 631). Cases of delirium or psychosis were defined by the Diagnostic and Statistical Manual of Mental Disorders-IV criteria, and the Naranjo scale (score ≥ 1) was used to determine the probability of the adverse drug reaction being related to fluoroquinolones. A bivariate analysis of covariates followed by a multivariate logistic regression was used to determine predisposing factors to the development of delirium/psychosis. RESULTS: The mean age of the population was 71.5 years (range: 22-95). Fluoroquinolone-associated delirium/psychosis occurred in 3.7% of the inpatients studied (n = 23). The median Naranjo score was 3 indicating a possible association. Psychosis/delirium occurred in 3.6% of ciprofloxacin-treated patients (n = 14/391), 4.5% of patients-treated with moxifloxacin (n = 9/200), and 0% of those receiving levofloxacin (n = 0/40); p = 0.4. Significant risk factors for development of delirium/psychosis in patients receiving a fluoroquinolone in the multivariate logistical regression included typical antipsychotic use (OR, 5.4; 95% CI: 1.4-16.7) and age. A 10-year increase in age was associated with a 1.8-fold greater odds of a neuropsychiatric event. CONCLUSIONS:Fluoroquinolones may be more commonly associated with delirium/psychosis than originally reported in this veteran population. Caution should be used when prescribing a fluoroquinolone for patients on typical antipsychotics and those of advanced age. Published by Elsevier Inc.
Entities:
Keywords:
Adverse Drug Events; Antibiotics; Drug Safety; Fluoroquinolones; Infectious Diseases; Medication Safety
Authors: Hae Reong Kim; MinDong Sung; Ji Ae Park; Kyeongseob Jeong; Ho Heon Kim; Suehyun Lee; Yu Rang Park Journal: Medicine (Baltimore) Date: 2022-06-24 Impact factor: 1.817
Authors: David Beckmann; Kelsey Leigh Lowman; Jessica Nargiso; James McKowen; Lisa Watt; Amy M Yule Journal: Child Adolesc Psychiatr Clin N Am Date: 2019-09-23
Authors: Flory Tsobo Muanda; Manish M Sood; Matthew A Weir; Jessica M Sontrop; Fatemeh Ahmadi; Elisa Yoo; Richard B Kim; Michael S Silverman; Gregory A Knoll; Amit X Garg Journal: JAMA Netw Open Date: 2022-08-01
Authors: Charles E Gaber; Alan C Kinlaw; Jessie K Edwards; Jennifer L Lund; Til Stürmer; Sharon Peacock Hinton; Virginia Pate; Luther A Bartelt; Robert S Sandler; Anne F Peery Journal: Ann Intern Med Date: 2021-02-23 Impact factor: 51.598